All In Biotech

Drug Trial Radar · NCT05489328

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

A PHASE 1, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE

Last checked: Nov 19, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

394

Actual

Start

Aug 15, 2022

Primary completion

Oct 7, 2022

Study completion Oct 7, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.

Conditions

  • Pneumococcal Disease

Interventions

  • Candidate-1Other

    Biological

  • Candidate-2Other

    Biological

  • Candidate-3Other

    Biological

  • Candidate-4Other

    Biological

  • Candidate-5Other

    Biological

  • Candidate-6Other

    Biological

  • Candidate ControlOther

    Biological

  • 13vPnCBiological

    13-valent pneumococcal conjugate vaccine

  • PCV15Biological

    15-valent pneumococcal conjugate vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Local Reactions Within 7 Days After Administration of Study InterventionTime frame: Within 7 days after study intervention
  2. Percentage of Participants With Systemic Events Within 7 Days After Administration of Study InterventionTime frame: Within 7 days after study intervention
  3. Percentage of Participants With Adverse Events (AE) Within 1 Month After Administration of Study InterventionTime frame: Within 1 month after study intervention
  4. Percentage of Participants With Serious Adverse Events (SAE) Within 1 Month After Administration of Study InterventionTime frame: Within 1 month after study intervention

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Orange County Research Center

    Tustin, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Clinical Research Consulting

    Milford, Connecticut

  • Proactive Clinical Research,LLC

    Fort Lauderdale, Florida

  • Indago Research & Health Center, Inc

    Hialeah, Florida

  • Qps-Mra, Llc

    South Miami, Florida

  • Centennial Medical Group

    Elkridge, Maryland

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan

  • Prism Research LLC dba Nucleus Network

    Saint Paul, Minnesota

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • Clinical Trials of Texas, LLC

    San Antonio, Texas

  • Diagnostics Research Group

    San Antonio, Texas

  • IMA Clinical Research San Antonio

    San Antonio, Texas

  • DM Clinical Research

    Tomball, Texas

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah

  • Alliance for Multispecialty Research, LLC

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.